Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results.

MLA

Xia, Zu-Guang, et al. “Phase 2 Study of Pegylated Liposomal Doxorubicin plus Cyclophosphamide, Vincristine/Vindesine, and Prednisone in Newly Diagnosed PTCL: 8-Year Results.” The Oncologist, vol. 29, no. 9, Sept. 2024, p. 819. EBSCOhost, https://doi.org/10.1093/oncolo/oyae108.

APA

Xia, Z.-G., Lv, F.-F., Zhang, Q.-L., Liu, Y.-Z., Zhang, S.-J., Liu, C., Li, X.-Q., Wen, Y., Wu, Z.-Y., Hong, X.-N., Guo, Y., & Cao, J.-N. (2024). Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results. The Oncologist, 29(9), 819. https://doi.org/10.1093/oncolo/oyae108

Chicago

Xia, Zu-Guang, Fang-Fang Lv, Qun-Ling Zhang, Yi-Zhen Liu, Sheng-Jian Zhang, Chang Liu, Xiao-Qiu Li, et al. 2024. “Phase 2 Study of Pegylated Liposomal Doxorubicin plus Cyclophosphamide, Vincristine/Vindesine, and Prednisone in Newly Diagnosed PTCL: 8-Year Results.” The Oncologist 29 (9): 819. doi:10.1093/oncolo/oyae108.